Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TATUM-T vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have achieved menarche, are seeking contraception, and have failed topical therapy
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 m L/min) requiring dose adjustment
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethynodiol diacetate is rapidly deacetylated to ethynodiol and then extensively metabolized via reduction, hydroxylation, and conjugation; primary enzyme is CYP3A4. Ethinyl estradiol is metabolized primarily by CYP3A4 and undergoes phase II conjugation (glucuronidation and sulfation).
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%)
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
92-95% bound to albumin and alpha-1-acid glycoprotein
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
0.3-0.5 L/kg (indicating moderate tissue distribution; primarily in extracellular fluid)
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 90% (high first-pass metabolism negligible); Sublingual: 95%; Intravenous: 100%
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use is not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in Child-Pugh class C (severe hepatic impairment) and in women with active liver disease. For Child-Pugh A or B, use is not recommended due to impaired hormone metabolism. If used, monitor liver function closely.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for use before menarche. For post-menarche adolescents, use the same standard adult dosing regimen. Safety and efficacy established in females aged 16-35 years.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use after menopause. No geriatric-specific dose adjustment is available.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and with smoking (especially in women over 35 years of age). Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders: Venous thromboembolism, arterial thromboembolism (e.g., stroke, myocardial infarction); discontinue if symptoms occur.,Hepatic disease: Discontinue if jaundice develops; use with caution in patients with impaired liver function.,Risk of liver tumors (benign and malignant); discontinue if right upper quadrant pain or signs of intra-abdominal bleeding.,Elevated blood pressure: Monitor and discontinue if hypertension occurs.,Carbohydrate metabolism: May decrease glucose tolerance; monitor diabetic patients.,Hyperkalemia: Risk in patients with renal impairment or concomitant potassium-sparing diuretics due to drospirenone component; TATUM-T does not contain drospirenone, so minimal risk.,Gallbladder disease: May worsen existing disease.,Hereditary angioedema: May exacerbate.,Chloasma: May occur, avoid sun exposure.,Retinal thrombosis: Discontinue if unexplained partial or complete vision loss.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes per day) in women over 35 years of age
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific food interactions. Avoid excessive copper supplements as the IUD releases copper locally; systemic absorption is minimal but caution in Wilson's disease.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformations and embryotoxicity. In human pregnancy, therapeutic use of copper is generally not associated with major teratogenic risk when used within recommended doses. However, data are limited. For the first trimester, there is a theoretical risk of copper toxicity affecting organogenesis; for second and third trimesters, risks include potential for copper accumulation and fetal hepatic toxicity. Zinc is essential but high doses may interfere with copper absorption. Overall, use only if clearly needed.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Copper is excreted into breast milk in small amounts and is a normal component of human milk. Zinc is also excreted. The M/P ratio for copper is approximately 0.1-0.3 and for zinc is about 0.5-1.0. At therapeutic doses, TATUM-T is unlikely to cause adverse effects in a breastfed infant. However, caution is advised due to potential for copper or zinc accumulation if maternal doses are high. Consider monitoring infant copper/zinc levels if prolonged use.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No established dosage adjustments are recommended for TATUM-T during pregnancy. However, pregnancy may alter copper metabolism with increased ceruloplasmin, potentially leading to lower free copper levels. Monitor serum copper levels to ensure therapeutic efficacy and avoid deficiency. If copper levels drop, consider increasing dose under medical supervision. Zinc dosing may remain unchanged.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
TATUM-T is a copper-containing intrauterine device (IUD) for long-term contraception (up to 10 years). It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. Mechanism involves copper-induced sperm toxicity and inhibition of implantation. May be used in nulliparous women. Counsel patients about expected bleeding pattern changes: increased menstrual flow and spotting initially. Monitor for IUD expulsion or perforation, especially postpartum. Do not use in Wilson's disease or copper allergy.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
TATUM-T provides effective contraception for up to 10 years but does not protect against STDs; use condoms for protection.,You may experience heavier periods and spotting, especially in the first 3-6 months after insertion.,Check for the IUD strings after each menstrual period to ensure it is in place.,If you miss a period or have symptoms of pregnancy, contact your healthcare provider immediately.,Insertion may cause cramps and discomfort that typically resolve within a few hours to days.,Seek medical attention if you have severe pelvic pain, foul-smelling discharge, or fever, which could indicate infection.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TATUM-T vs ALTAVERA, answered by our medical review team.
TATUM-T is a Oral Contraceptive that works by TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TATUM-T and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TATUM-T is: One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TATUM-T and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TATUM-T is classified as Category C. TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformatio. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.